Phase 3 N=400 Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
General Anesthesia
Primary: Success Rate of General Anesthesia Induction — 253; 128 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=99 Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
COPD · COPD Exacerbation · COPD Exacerbation Acute
Primary: Change in St. George Respiratory Questionnaire (SGRQ) Scores — 39.02; 45.06 score on a scale
Phase 3 N=886 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Renal Cell Cancer
Primary: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants — 13.8; 7.2 Months…
Phase 3 N=18 Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
CTX
Primary: Change From Baseline in Urine 23S-Pentol During the Two Double-Blind Periods — 7.18; 6.96; 7.45; 10.34 natural log of ng/mL — p=<0.0001
Phase 3 N=602 PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
HIV-1 Infection
Primary: Physical Function: Rate of Change in Chair Rise Rate — -0.035; 0.07 rises/minute per year — p=0.31
Phase 3 N=152 An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Schizophrenia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36; 45 Participants
Phase 3 N=207 Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Obesity
Primary: Change in Body Weight (Percentage [%]) — -14.4; -2.7 Percentage (%) of body weight — p=<0.0001
Phase 3 N=245 Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders
Cognitive Disorders
Primary: Average MoCA Score. — 20.7; 21.7; 24.6; 24.5 score on a scale — p=0.0006
Phase 3 N=399 Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Vascular Dementia
Primary: Change in Mean Montreal Сognitive Assessment (MoCA) Score — 17.0; 17.3; 20.5; 19.2 score on a scale — p=<0.0001
Phase 3 N=47 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. — 17; 6…
Phase 3 N=167 Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
Knee Osteoarthritis · Pain Management
Primary: NRS Scores Through 96 Hours Post-surgery — 594.4; 650.1 units on a scale*hours — p=0.0074
Phase 3 N=58,747 Azithromycin-Prevention in Labor Use Study (A-PLUS)
Maternal Death · Maternal Infections Affecting Fetus or Newborn · Neonatal SEPSIS
Primary: Maternal Death or Sepsis Within 6 Weeks (42 Days) Post-delivery in Intervention vs. Placebo Group. — 227; 344 Participants — p=<0.001
Phase 3 N=91 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
Congenital Adrenal Hyperplasia
Primary: Safety and Tolerability - Number of Participants With Adrenal Insufficiency — 25; 41 Participants
Phase 3 N=400 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 1.0; 1.0; 0.0; 0.5 Percentage of participants
Phase 3 N=546 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Pancreatic Intraductal Papillary-Mucinous Neoplasm
Primary: Overall Survival (Percentage of Participants Alive) [Phase II] — 29.9; 28.1 months — p=0.62